|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,971 GBX | +5.45% |
|
+10.19% | +13.45% |
| 03:40pm | ASTRAZENECA : UBS maintains a Sell rating | ZD |
| 03:22pm | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
PARIS (Reuters) - The situation regarding the COVID-19 vaccine being developed by AstraZeneca is generally encouraging, even though a new trial will be needed, said AstraZeneca France president Olivier Nataf on Friday.
"We are in a context that is encouraging," Nataf told RTL radio.
AstraZeneca nevertheless faces questions about its success rate, which some experts say could hinder its chances of gaining speedy U.S. and EU regulatory approval.
(Reporting by Sudip Kar-Gupta; Editing by David Goodman)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.45% | 219B | |
| +24.48% | 562B | |
| -6.37% | 358B | |
| +19.38% | 322B | |
| +7.47% | 297B | |
| +6.09% | 199B | |
| -10.55% | 196B | |
| -10.98% | 149B | |
| -6.96% | 146B | |
| +2.15% | 117B |
ASTRAZENECA PLC 
